In addition, a prospective observational study of dyslipidemic patients with diabetes or hyperglycemia showed that bezafibrate significantly reduces haemoglobin A1c (HbA1c) concentration as a function of baseline HbA1c levels, regardless of concurrent use of antidiabetic drugs.
The research examined how bezafibrate affects HbA1c levels in individuals with both high blood sugar and high cholesterol, finding that it lowers HbA1c regardless of whether they are taking other diabetes medications.